Evoke Pharma Reports Record Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
Evoke Pharma, Inc.
80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
01 août 2022 08h30 HE
|
Evoke Pharma, Inc.
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif.,...
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
12 nov. 2020 17h02 HE
|
Processa Pharmaceuticals Inc.
HANOVER, MD., Nov. 12, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
03 nov. 2020 09h20 HE
|
Processa Pharmaceuticals Inc.
HANOVER, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing...
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
19 sept. 2019 08h30 HE
|
CinRx Pharma
CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (“CinDome”), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first...
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
03 nov. 2015 11h50 HE
|
Neurogastrx
CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...
Tranzyme Pharma Announces Top-Line Results of TZP-102 Phase 2b Trial
15 nov. 2012 05h10 HE
|
Ocera Therapeutics, Inc.
Preliminary Analysis Indicates Trial Did Not Meet Primary Endpoint
Tranzyme to Host Conference Call Today at 8:00 am ET
RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- ...
Tranzyme Pharma Announces Third Quarter 2012 Financial Results
08 nov. 2012 16h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class...
Tranzyme Pharma to Host Third Quarter 2012 Financial Results Conference Call on Friday, November 9, 2012
25 oct. 2012 05h10 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, November 9, 2012 at 8:30 am ET to discuss...
Tranzyme Pharma to Present at BIO Investor Forum on October 10, 2012
03 oct. 2012 13h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the 11th Annual BIO Investor...